Basilea Pharmaceutica AG
BPMUF
$67.75
$6.4110.45%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 35.40% | 20.13% | 75.71% | 77.95% | -9.52% |
| Total Other Revenue | 388.49% | 333.39% | 263.80% | 268.42% | -31.85% |
| Total Revenue | 49.38% | 32.53% | 83.35% | 85.68% | -10.68% |
| Cost of Revenue | 32.53% | 17.58% | -11.67% | -10.55% | 63.39% |
| Gross Profit | 84.82% | 63.97% | 15,231.59% | 15,427.28% | -54.29% |
| SG&A Expenses | 24.12% | 10.12% | 1.08% | 2.36% | -1.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.64% | 15.90% | -9.40% | -8.24% | 42.38% |
| Operating Income | 180.89% | 149.21% | 421.32% | 425.40% | -75.29% |
| Income Before Tax | 189.51% | 156.86% | 349.34% | 352.52% | -77.15% |
| Income Tax Expenses | 128.96% | 125.69% | -23,155.21% | -23,510.42% | -49,538.67% |
| Earnings from Continuing Operations | -16.46% | -25.89% | 368.03% | 371.43% | -35.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.46% | -25.89% | 368.03% | 371.43% | -35.26% |
| EBIT | 180.89% | 149.21% | 421.32% | 425.40% | -75.29% |
| EBITDA | 170.96% | 140.39% | 467.66% | 472.34% | -74.08% |
| EPS Basic | -17.87% | -26.83% | 366.05% | 369.42% | -35.57% |
| Normalized Basic EPS | 184.69% | 153.60% | 347.50% | 350.66% | -77.26% |
| EPS Diluted | -19.60% | -23.81% | 322.69% | 325.51% | -29.11% |
| Normalized Diluted EPS | 168.77% | 156.39% | 315.53% | 318.28% | -75.51% |
| Average Basic Shares Outstanding | 1.71% | 1.29% | 0.74% | 0.74% | 0.47% |
| Average Diluted Shares Outstanding | 7.71% | 0.19% | 15.69% | 15.69% | -6.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |